Brain imaging study of Parkinson's disease with LRRK2 gene mutations
Part of Brain & nervous system clinical trials.
This research study uses advanced MRI brain imaging to understand how a specific gene mutation (LRRK2) affects certain brain chemicals in people with Parkinson's disease. The goal is to learn more about how this genetic form of Parkinson's works, which could help develop better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 45 years or older
- You have been diagnosed with Parkinson's disease using standard diagnostic criteria
- You have a confirmed LRRK2 gene mutation (documented by a neurologist or genetic testing)
- You can safely undergo MRI scanning (no pacemakers, metal implants, or severe claustrophobia)
- You are not currently taking certain Parkinson's medications (anti-cholinergic drugs or cholinesterase inhibitors)
- You have not had deep brain stimulation surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a registry that collects information from people with Parkinson’s who have specific LRRK2 gene changes. It helps researchers understand how this genetic form of Parkinson’s behaves over time.
This trial tests an experimental drug called NEU-411 for people with early Parkinson's disease who have a specific genetic change (LRRK2). It aims to see if the drug can slow the disease progression.
This study looks at people with Parkinson’s who carry a specific genetic change in the GBA gene. It uses several tests (including brain scans) to understand the disease better and may help guide future treatments.
This study looks at how certain genes might affect thinking and behavior in people with Parkinson's disease. If you have Parkinson's, take Parkinson's medication, and have had genetic testing, you may be able to join.
This study looks at how people with Parkinson’s adapt their movements and how their brain sensorimotor system works. It may help researchers improve understanding of Parkinson’s and refine movement-focused therapies.
This study is building a large, detailed group of people—some with Parkinson’s and some at higher risk—to understand early changes over time. It uses brain imaging (DaTscan SPECT), sometimes spinal fluid tests (lumbar puncture), and genetic information to help researchers better measure disease and develop future treatments.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.